Company Overview and News

2
Blackstone Mortgage Trust: Buying This 7.7%-Yielding REIT Is A No-Brainer

2018-10-15 seekingalpha
I doubled down on Blackstone Mortgage Trust, Inc. (BXMT) last week because I think the market sell-off is a good opportunity to load up on high-quality income vehicles with potential for dividend and capital growth. Blackstone Mortgage Trust has a large floating-rate debt investment portfolio that is set up to deliver net interest income gains in a rising rate environment. Further, BXMT has excellent dividend coverage for an almost eight percent yielding REIT, and I can even see a dividend hike on the horizon.
BXMT 511505 CAPITALT

4
A Top Commercial Mortgage REIT Pick That Yields 8.9%

2018-10-15 seekingalpha
In our REIT Lab we cover most all commercial mortgage REITs, and the sector can be further broken down into two categories: pure balance sheet lender and balance sheet/conduit lender.
BXMT LADR TRTX 511505 CAPITALT STWD ACRE STWD.WI

 
IIFL Holdings, Infibeam, Tata Steel, NIIT Tech, MM Financial top losers among BSE Group A stocks

2018-10-11 moneycontrol
Selling pressure has once again intensified as the benchmark indices have slipped over 2 percent on the back of weak global cues and with the rupee hitting a new record low against the dollar.
523405 NIITTECH IDKQY IIFL 532636 HIGHGROUND PUNJCOMMU 535789 IBULHSGFIN 532541 500470 TTST TATASTEEL TATLY 511505 CAPITALT 517080 500346 JMFINANCIL

3
Blackstone Mortgage Trust: Still A Buy?

2018-09-24 seekingalpha - 1
Blackstone Mortgage Trust, Inc. (BXMT) remains a promising income vehicle during the current rate hiking cycle. Blackstone Mortgage Trust has invested in floating-rate loans that are poised to produce higher net interest income as the FED moves along the interest curve. Further, Blackstone Mortgage Trust continues to benefit from strong demand for new commercial real estate loans, suggesting that the investment thesis is still intact.
BXMT 511505 CAPITALT

16
Annaly Capital's Dividend And Valuation Compared To 19 mREIT Peers (Includes Q4 2018 And 2019 Dividend Projections) - Part 2

2018-09-24 seekingalpha - 1
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to 19 mREIT peers.
ANH NYMTO ORC CHMI NYMTP AI CIM CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT

 
Capital Trust Limited - AGM/Book Closure

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
511505 CAPITALT

2
What Is A REIT And How Are Dividends Received From A REIT Taxed?

2018-09-03 seekingalpha
This year, we started a financial education series geared towards educating beginning investors and, more specifically, beginning dividend growth investors. Our first two articles explain what a dividend is and the dividend payout ratio (and how to calculate it). In this article, we will take a deeper dive into one specific type of holding that can be found in many dividend investors' portfolio. This holding typically pays a higher dividend, which is why dividend investors are always on the lookout for a great one.
ARI NLY BXMT 511505 CAPITALT

11
'Little Brother' Blackstone Is Hitting All Cylinders

2018-08-30 seekingalpha - 1
I learned early in life that big brothers can be a competitive advantage, especially if you know how to “play the system."
BXMT CPLG.WI CPLG JPM LADR 511505 CAPITALT STWD PFE STWD.WI

12
Kevin's Q2 2018 Portfolio Update: In The Green

2018-08-19 seekingalpha
In my portfolio introduction, I introduced Seeking Alpha to my real money, REIT-heavy portfolio which had 9 positions. Three months later, most of the portfolio has had an amazing quarter and 3 new positions have been added. With my REIT ‘base’ down, I am now looking ahead to opening positions outside of the REIT space. Without further ado, here is how the portfolio is looking as of market close on Friday, August 17th
JCP ARI TWX TWC STWD.WI SHLD BXMT T LADR 511505 CAPITALT STWD ACRE

17
Comparing Annaly Capital's BV, Dividend, And Valuation To 20 mREIT Peers (Post Q2 2018 Earnings) - Part 1

2018-08-15 seekingalpha - 2
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT

2
Blackstone Mortgage Trust: This 7.5%-Yielding CRE Finance REIT Is Still A Buy

2018-08-13 seekingalpha
Blackstone Mortgage Trust, Inc. (BXMT) is a promising income vehicle for investors that seek high, recurring dividend income and capital growth from one of the leading commercial real estate finance REITs in the country. Blackstone Mortgage Trust has a strong, largely floating rate loan investment portfolio that is poised to deliver net interest income gains in a rising rate environment. I consider the dividend to have a high margin of dividend safety, at least as long as U.
BXMT 511505 CAPITALT

 
Capital Trust Limited - Outcome of Board Meeting

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
511505 CAPITALT

 
Capital Trust Limited - Financial Result Updates

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
511505 CAPITALT

 
NBCC, IOC, Coal India, Corp Bank results eyed

2018-08-11 thehindubusinessline
Over 220 companies will declare their April-June results on Saturday. These include Adani Green, Amara Raja, Andhra Cements, Ashima, Balkrishna Ind, Capital Trust, Coal India, Corporation Bank, Dalmia Bharat, Finolex, Godfrey Phillips, India Cements, IOC, MRPL, NBCC (India), Kirloskar, KSK Energy, PAE, Sarda Energy, Shyam Telecom, Suryalakshmi Cotton, Texmo Pipes, TVS Srichakra, VRL Logistics and VST Tillers.
ECQRY DALMIABHA 530005 ANDHRACEMT 533278 517411 539118 532179 505200 SHYAMTEL TVSSRICHAK VRLLOG CRPKY 533309 532141 511505 CAPITALT 509243 CORPBANK INDIACEM EICHERMOT CLNDY COALINDIA

4
The Best Vote Of Confidence Is Having 'Skin In The Game'

2018-08-06 seekingalpha
I am pleased to see this puppy bounce as I knew a long time ago that this company had all of the ingredients of something special.
BXMT LADR 511505 CAPITALT STWD STWD.WI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...